Sumitomo Dainippon Pharma announces Investment in a New Venture Capital Fund
Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
"Corporate profile" An English version and a Japanese version are updated.
Transfer of Marketing Rights for “Inteban”, “Catlep” and “Drenison”
Posted Factbook 2014
Sumitomo Dainippon Pharma announces Change of the Company’s English trade name
A Message from the President
Board of Directors and Executive Officers